fanasil, pyrimethamine drug combination has been researched along with Lupus Erythematosus, Systemic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, H; Iida, N; Maeda, M; Mori, K; Nawata, M; Sekigawa, I; Seta, N; Shimizu, T; Wada, R | 1 |
1 other study(ies) available for fanasil, pyrimethamine drug combination and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
A possible novel mechanism of opportunistic infection in systemic lupus erythematosus, based on a case of toxoplasmic encephalopathy.
Topics: Adult; Animals; Anti-Infective Agents; Antibodies, Protozoan; Cerebral Cortex; Drug Combinations; Female; Humans; Immunocompromised Host; Lupus Erythematosus, Systemic; Opportunistic Infections; Prednisolone; Pyrimethamine; Sulfadoxine; Sulfamonomethoxine; Tomography, X-Ray Computed; Toxoplasma; Toxoplasmosis, Cerebral; Treatment Outcome | 2002 |